Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.
Mol Cancer Ther
; 18(3): 642-655, 2019 03.
Article
en En
| MEDLINE
| ID: mdl-30679390
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Cistadenocarcinoma Seroso
/
Proteínas Proto-Oncogénicas c-bcl-2
/
Proteína bcl-X
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Mol Cancer Ther
Asunto de la revista:
ANTINEOPLASICOS
Año:
2019
Tipo del documento:
Article